Hepatic tumors in Iranian children: Characteristics and survival predictors

Fateme Ziyaee1, Seyed Mohsen Dehghani2, Mehdi Forooghi3

  • 1Department of Pediatric Gastroenterology, Shiraz University of Medical Sciences, Shiraz, Iran.

PubMed

Insights

Pediatric hepatic tumors, primarily hepatoblastoma, present with abdominal symptoms. Hepatocellular carcinoma (HCC) and jaundice indicate a poor prognosis in children with liver masses.

Area of Science:

  • Pediatric Oncology
  • Hepatobiliary Surgery
  • Clinical Epidemiology

Background:

  • Hepatic tumors are uncommon in pediatric populations.
  • Understanding their characteristics is crucial for effective management.
  • This study investigates liver masses in children.

Purpose of the Study:

  • To determine the characteristics of pediatric liver masses.
  • To identify independent predictors of survival in children with hepatic tumors.

Main Methods:

  • Retrospective review of medical records for children under 18.
  • Data collected from January 2008 to December 2023 at two referral centers in Iran.
  • Inclusion criteria: confirmed diagnosis of hepatic tumor.

Main Results:

  • 153 children diagnosed with hepatic tumors; median age 2 years.
  • Hepatoblastoma (64.5%) was most common, followed by hepatocellular carcinoma (HCC, 9.9%).
  • Abdominal pain, distension, palpable mass, and fever were common symptoms. HCC and jaundice predicted poor prognosis.

Conclusions:

  • Pediatric hepatic tumor characteristics align with existing literature.
  • Abdominal pain, distension, HCC diagnosis, and jaundice are independent predictors of poor prognosis.
  • Early identification of these factors can guide treatment strategies.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
414
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
274
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
870